AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25037695
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg Q2W before up-titration at week 12.
Trial: 25037695
Drug: Injection site
RxNorm normalized name: Dual Injection Site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection site reactions for Alirocumab.
Trial: 25037695
Drug: Injection site
RxNorm normalized name: Dual Injection Site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection site reactions for Ezetimibe.
Trial: 19574013
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of MMF (mycophenolate mofetil)
Trial: 19574013
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg bid of MMF (mycophenolate mofetil)
Trial: 15022114
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy with Gemcitabine
Trial: 11885184
Drug: Hydroxyapatite-coated grooved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyapatite-coated grooved implants
Trial: 12500876
Drug: Hydroxyapatite grooved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyapatite grooved and screw implants
Trial: 12500876
Drug: Hydroxyapatite-coated cylinder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyapatite-coated cylinder and grooved implants
Trial: 12500876
Drug: Non-hydroxyapatite-coated implants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-hydroxyapatite-coated implants
Trial: 7970010
Drug: Tizanidine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine (maximum dosage of 36 mg/d)
Trial: 30009640
Drug: Diclofenac 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 0.1% (four times daily for 28 days)
Trial: 30009640
Drug: Bromfenac 0.09%
RxNorm normalized name: Bromfenac 0.09% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac 0.09% (twice daily for 14 days)
Trial: 30009640
Drug: Steroid-antibiotic combination
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-antibiotic combination (Control Group 3)
Trial: 28440351
Drug: HyperSPACE (Hyper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HyperSPACE (Hyper SPectral Analysis for Characterization in Echography) method applied before and after laser treatment
Trial: 26234471
Drug: Rosehip powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosehip powder (3 capsules/day for 12 weeks)
Trial: 26234471
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 identically appearing capsules/day for 12 weeks)
Trial: 12687385
Drug: Once-daily beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily beclomethasone dipropionate (BDP), 400 micro g/day
Trial: 12687385
Drug: Twice-daily beclomethasone
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily beclomethasone dipropionate (BDP), 400 micro g/day
Trial: 1513607
Drug: Loracarbef 30
RxNorm normalized name: Loracarbef
DrugBank: Loracarbef (DB00447)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loracarbef 30 mg/kg/day in two divided doses for 10 days
Trial: 1513607
Drug: Amoxicillin/clavulanate 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate 40 mg/kg/day in three divided doses for 10 days
Trial: 1513607
Drug: Loracarbef 30
RxNorm normalized name: Loracarbef
DrugBank: Loracarbef (DB00447)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loracarbef 30 mg/kg/day in two divided doses for 7 days
Trial: 1513607
Drug: Amoxicillin 40
RxNorm normalized name: amoxicillin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 40 mg/kg/day in three divided doses for 7 days
Trial: 24887336
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine (0.5 µg/kg, 1 mL)
Trial: 24887336
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (0.5 µg/kg, 20 mL)
Trial: 11831545
Drug: 175 mg
RxNorm normalized name: caffeine 175 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 175 mg rofecoxib
Trial: 6421778
Drug: Nutritional support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional support (1800 kcal, 70 g protein) by naso-jejunal tube for 7-10 days
Trial: 29437590
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality treatment (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Trial: 27722221
Drug: Immediate non-occlusally
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate non-occlusally loaded implants
Trial: 23169801
Drug: Intensive structured
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive structured care (computer assisted clinical profiling and risk target setting, intensified follow-up, stepwise drug titration)
Trial: 19709689
Drug: pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pioglitazone (30 mg/d, n = 19)
Trial: 19709689
Drug: rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (4 mg/d, n = 20)
Trial: 19709689
Drug: placebo (medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (medical nutrition therapy, n = 21)
Trial: 15004572
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ciprofloxacin and dexamethasone
Trial: 15004572
Drug: Artificial tear
RxNorm normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial tear solution (Tears Naturale)
Trial: 11303266
Drug: Ciprofloxacin, 500
RxNorm normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, 500 mg
Trial: 11303266
Drug: Cefixime, 400
RxNorm normalized name: Cefixime, 400 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime, 400 mg
Trial: 11303266
Drug: Ciprofloxacin (MICs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (MICs > or = 4.0 microg/mL)
Trial: 11303266
Drug: Ciprofloxacin (MICs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (MICs < 4.0 microg/mL)
Trial: 9164216
Drug: Radiotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy and chemotherapy (750 mg/m2 daily fluorouracil on days 1 to 5 and 29 to 33, and 15 mg/m2 mitomycin on day 1)
Trial: 7232842
Drug: Radiotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy and chemotherapy
Trial: 2438902
Drug: Thermochemotherapy (hyperthermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermochemotherapy (hyperthermia combined with chemotherapy)
Trial: 20397456
Drug: blood‐letting cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blood‐letting cupping plus herbal medicine
Trial: 17955168
Drug: Verum acupuncture
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum acupuncture (traditional Chinese medicine)
Trial: 8010718
Drug: High-dose folinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose folinic acid (FA) plus fluorouracil (FU)
Trial: 2658897
Drug: Mezlocillin therapy
RxNorm normalized name: mezlocillin
DrugBank: Mezlocillin (DB00948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mezlocillin therapy
Trial: 2658897
Drug: Ampicillin-gentamicin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-gentamicin therapy
Trial: 25099872
Drug: web- and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: web- and text messaging-based intervention providing online feedback and tailored text messages, up to two weekly messages for 3 months
Trial: 17309596
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + 500 mg azithromycin per day for 3 days (N=25)
Trial: 17309596
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + 250 mg metronidazole tid for 14 days (N=24)
Trial: 17309596
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + 20 mg doxycycline bid for 3 months (N=20)
Trial: 15125464
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg daily for H. pylori-positive patients (Hp+/ome)
Trial: 15125464
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg daily for H. pylori-negative patients (Hp-/ome)
Trial: 15125464
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg daily for H. pylori-negative patients (Hp-/erad)
Trial: 10457551
Drug: Single 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 800 mg injection of Pefloxacin (PF)
Trial: 8574175
Drug: Branched-chain amino
RxNorm normalized name: Branched-chain amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched-chain amino acids (L-leucine 12 g, L-isoleucine 6 g, L-valine 6 g daily)
Trial: 895002
Drug: new formulation
RxNorm normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: new formulation isolating beta-acetyldigoxin from potassium-magnesium-aspartate
Trial: 25788569
Drug: Low-dose human
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose human menopausal gonadotrophin (hMG) 37.5-75 IU per day
Trial: 25788569
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 50 mg/day from Day 3-7
Trial: 25788569
Drug: Low-dose human
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose human menopausal gonadotrophin (hMG)
Trial: 19153941
Drug: rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (4 to 8 mg daily)
Trial: 16953261
Drug: Cetilistat 60
RxNorm normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cetilistat 60 mg t.i.d.
Trial: 19461584
Drug: Cetilistat 120
RxNorm normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cetilistat 120 mg t.i.d.
Trial: 16953261
Drug: Cetilistat 240
RxNorm normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cetilistat 240 mg t.i.d.
Trial: 16953261
Drug: Cetilistat (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetilistat (all doses)
Trial: 15372383
Drug: Bier block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bier block with methylprednisolone (40 mg) and lidocaine (10 mL of 2% solution)
Trial: 11465642
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (21 mg patches)
Trial: 9604636
Drug: Acupuncture (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (15 treatments over 3 months)
Trial: 1620298
Drug: FUT-175 (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUT-175 (Group A: 20 mg every 12 hours for 4 days; Group B: 20 mg every 6 hours for 4 days; Group C: 40 mg every 6 hours for 4 days)
Trial: 1620298
Drug: FUT-175 (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUT-175 (higher doses: Groups B and C)
Trial: 6366808
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg serrapeptase 3 times on the day before operation, once on the night of the operation and 3 times daily for 5 days after operation
Trial: 23748117
Drug: Morphine (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.08 mg/kg)
Trial: 24331381
Drug: Subcutaneous yellow
RxNorm normalized name: yellow OB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous yellow fever virus (YFV) vaccination
Trial: 22529163
Drug: Cinacalcet HCl
RxNorm normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cinacalcet HCl therapy
Trial: 19243009
Drug: High-dose radiosurgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiosurgery (20 or 24Gy targeting the amygdala, hippocampus, and parahippocampal gyrus)
Trial: 19243009
Drug: Low-dose radiosurgery
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiosurgery (20 or 24Gy targeting the amygdala, hippocampus, and parahippocampal gyrus)
Trial: 19243009
Drug: Both high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both high-dose and low-dose radiosurgery
Trial: 19243009
Drug: High-dose and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose and low-dose radiosurgery
Trial: 17544497
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of platinum-based chemotherapy followed by surgery (CT-S)
Trial: 15066896
Drug: QI-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QI-therapy
Trial: 2540789
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy (M series: 131 patients)
Trial: 2540789
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance chemotherapy (NoM series: 134 patients)
Trial: 2540789
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with complete response to initial chemotherapy (99 patients)
Trial: 1954179
Drug: Initial chemotherapy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial chemotherapy
Trial: 836131
Drug: Foster care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foster care preparation
Trial: 28375507
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (All three vaccines concurrently)
Trial: 17007024
Drug: PegIFN‐alpha2a 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN‐alpha2a 180 mg subcutaneously once weekly for a year + Ribavirin 1200 mg
Trial: 17007024
Drug: IFN alpha‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN alpha‐2a 3 MU 3 times weekly + Ribavirin 1200 mg
Trial: 15017671
Drug: Rifampin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (300 or 600 mg daily)
Trial: 9292183
Drug: Topical nasal
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nasal steroid (budesonide)
Trial: 30886326
Drug: Bisoprolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (5 mg/day for 3 weeks)
Trial: 19935373
Drug: Standard exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard exposure everolimus (C0 3‐8 ng/mL) with low‐concentration cyclosporine A (C2 maintenance levels 350‐500 ng/mL)
Trial: 19935373
Drug: Higher exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher exposure everolimus (C0 8‐12 ng/mL) with very low‐concentration cyclosporine A (C2 maintenance levels 150‐300 ng/mL)
Trial: 16796694
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate (400 mg orally twice daily)
Trial: 15273706
Drug: Intermediate-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose cyclophosphamide (2 g/m(2)) plus lenograstim at 5 micrograms/kg (Cyclo-G-CSF group)
Trial: 15273706
Drug: Lenograstim alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenograstim alone at 10 micrograms/kg (G-CSF group)
Trial: 15273706
Drug: Intermediate-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose cyclophosphamide plus lenograstim (Cyclo-G-CSF group)
Trial: 15273706
Drug: Lenograstim alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenograstim alone (G-CSF group)
Trial: 10860226
Drug: Low-tidal-volume ventilation
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-tidal-volume ventilation (6 mL/kg)
Trial: 10860226
Drug: Traditional-tidal-volume ventilation
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional-tidal-volume ventilation (12 mL/kg)
Trial: 25340383
Drug: Maximal medical
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal medical therapy
Trial: 2866830
Drug: Dezocine 5
RxNorm normalized name: dezocine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dezocine 5 mg
Trial: 2866830
Drug: Dezocine 10
RxNorm normalized name: dezocine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dezocine 10 mg
Trial: 2871049
Drug: Dezocine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dezocine 2.5 mg
Trial: 31494070
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of APTD and anodal tDCS
Trial: 24929926
Drug: Short-term Cognitive-Behavioral
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term Cognitive-Behavioral Treatment (CBT)
Trial: 18955835
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (154 mEq/l infusion)
Trial: 18955835
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride (0.9% solution)
Trial: 16551862
Drug: 5,6-Dimethylxanthenone-4-acetic acid
RxNorm normalized name: 5,6-Dimethylxanthenone-4-acetic acid
DrugBank: Vadimezan (DB06235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) at 1,200 mg m(‐2)
Trial: 10839291
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment in every arm
Trial: 10839291
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment arm
Trial: 6120703
Drug: flunitrazepam 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flunitrazepam 0.03 mg/kg
Trial: 6120703
Drug: midazolam 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 0.15 mg/kg
Trial: 28063503
Drug: Glutamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (0.25 g/kg)
Trial: 25891654
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of placental extract gel (group S)
Trial: 23810688
Drug: Shenqi particle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi particle (9.6 g 3 times per day)
Trial: 23810688
Drug: Prednisone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (1 mg/kg/d tapering to 0.17 mg/kg/d) and cyclophosphamide (total dose of 9-12 g/m²)
Trial: 8198981
Drug: Recombinant interleukin
RxNorm normalized name: Recombinant interleukin 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interleukin 2 (rIL-2) therapy
Trial: 2885357
Drug: Terfenadine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 300 mg bid for 3 days
Trial: 2885357
Drug: Terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 60 mg bid for 3 days
Trial: 2885357
Drug: Chlorpheniramine 8
RxNorm normalized name: CODEINE 54.3/CHLORPHENIRAMINE 8MG SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine 8 mg three times a day for 3 days
Trial: 29248859
Drug: Edoxaban and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban and Warfarin
Trial: 28494895
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion at a dose of 2‐5μg/kg/min
Trial: 28494895
Drug: Labetalol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol infusion at a dose of 0.5‐2mg/min
Trial: 21129239
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg ATP per day for 28 days
Trial: 21129239
Drug: 1250 mg
RxNorm normalized name: bran 1250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250 mg ATP per day for 28 days
Trial: 21129239
Drug: 5000 mg
RxNorm normalized name: bran 5000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 mg ATP per day for 28 days
Trial: 21129239
Drug: 5000 mg
RxNorm normalized name: bran 5000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 mg ATP on days 0 and 28
Trial: 21129239
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg ATP per day for 28 days (control)